Back to Search

Continued Deucravacitinib Treatment for Lupus

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Recruiting Phase 4 Interventional Study
Systemic Lupus Erythematosus (SLE) Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
More trials: Lupus clinical trials· Lupus trials in New York
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
35 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Who this trial is looking for

This trial is looking for people who have lupus and want to continue their treatment with Deucravacitinib. To join, you need to have finished certain previous studies and be assessed by a doctor to see if you can benefit from further treatment.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have completed Study IM011074 or Study IM011132
  • My doctor thinks I can benefit from Deucravacitinib
  • I received treatment within the last 60 days

You may not be able to join if

  • I have a medical condition that makes me unsuitable for this trial
  • I have active Tuberculosis (TB)

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria * Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period. * Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib. * Participants must hav…
Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286

Clinical.Trials@bms.com

CONTACT

First line of the email MUST contain NCT # and Site #.

CONTACT

NCT ID: NCT06875960 Source: ClinicalTrials.gov